Verrica Pharmaceuticals

VRCAPhase 2

Verrica Pharmaceuticals is a US-based, publicly traded company dedicated to transforming the treatment landscape for viral skin diseases and dermatologic oncology. Its core achievement is the 2023 FDA approval and commercialization of YCANTH for molluscum contagiosum, a significant milestone addressing a large pediatric population. The company's strategy involves expanding YCANTH's label into common warts and developing VP-315, an oncolytic peptide licensed from Lytix Biopharma, for non-surgical treatment of basal cell carcinoma. Verrica is positioning itself as a leader in medical dermatology with a focus on accessible, in-office procedures.

Market Cap

$93.6M

Focus

RNA & Gene TherapySmall Molecules

VRCA · Stock Price

USD 5.4577.95 (-93.47%)

Historical price data

AI Company Overview

Technology Platform

Proprietary drug-device combination platform featuring GMP-controlled topical formulations (e.g., cantharidin) delivered via single-use applicators for precise in-office administration, and an oncolytic peptide (VP-315) for intratumoral immunogenic cell death.

Pipeline Snapshot

1 drug in pipeline

Drug	Indication	Stage	Watch
Part 1: VP-315 3 Day Dosing/Week + Part 2: VP-315 3 Day Dosing/Week - Loading Do...	Basal Cell Carcinoma	Phase 2

Funding History

Total raised: $195M

PIPE$50MUndisclosedAug 15, 2021

IPO$86MUndisclosedJun 28, 2018

Series B$34MUndisclosedJun 15, 2016

Series A$25MUndisclosedOct 15, 2013

Opportunities

Significant growth opportunities exist from expanding YCANTH's label into the massive common warts market (~22M US cases) and from developing VP-315 as a first-in-class, non-surgical treatment for common skin cancers.

International partnerships, like the one with Torii in Japan, provide additional revenue streams and global market penetration.

Risk Factors

Key risks include commercial execution challenges for YCANTH's launch, clinical trial failures in the Phase 3 common warts program or the VP-315 oncology asset, and continued cash burn requiring further financing.

The company also faces competition from off-label therapies and potential future approved products.

Competitive Landscape

YCANTH is first-to-market in FDA-approved molluscum treatment, competing against off-label therapies. In common warts, it aims to be the first FDA-approved drug against a backdrop of OTC products and procedures. VP-315 would compete against surgical standards (excision, Mohs) and topical drugs in basal cell carcinoma, differentiating itself as an immune-activating, injectable non-surgical option.